Oruka Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Oruka Therapeutics, Inc. (ORKA) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $2.11 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-03-12
- Oruka Therapeutics, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $2.11M.
- Oruka Therapeutics, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2023 was $0.00.
- Oruka Therapeutics, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Oruka Therapeutics, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2021 was $560.00K, a 193.19% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 11 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 103 month |
|---|---|---|---|
| 2025-12-31 | $2.11M 10-K · filed 2026-03-12 | ||
| 2024-12-31 | $2.84M 10-K · filed 2026-03-12 | ||
| 2023-12-31 | $0.00 10-K · filed 2024-02-01 | ||
| 2022-12-31 | $0.00 10-K · filed 2024-02-01 | ||
| 2021-12-31 | $560.00K 10-K · filed 2023-02-24 | ||
| 2020-12-31 | $191.00K 10-K · filed 2022-03-14 | ||
| 2019-12-31 | $31.00K 10-K · filed 2021-03-18 | ||
| 2018-12-31 | $144.00K 10-K · filed 2020-02-18 | ||
| 2017-12-31 | $303.00K 10-K · filed 2019-02-27 | ||
| 2016-12-31 | $268.00K 10-K · filed 2018-03-22 | ||
| 2015-12-31 | $181.00K 10-K · filed 2017-03-21 | ||
| 2014-12-31 | $171.00K 10-K · filed 2016-03-17 | ||
| 2013-12-31 | $133.00K 10-K · filed 2015-03-19 | $820.00K 10-K · filed 2014-03-20 | |
| 2012-12-31 | $687.00M 10-K · filed 2013-03-21 | ||
| 2011-12-31 | $71.00K 10-K · filed 2013-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |